Navigation Links
Afraxis Enters Collaboration with NIH as Part of Therapeutics for Rare and Neglected Disease Program
Date:9/26/2011

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- Afraxis, a San Diego-based biotechnology company developing drugs to treat rare genetic diseases through the modulation of p21-activated kinase (PAK), announced today that it has been selected to participate in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Disease (TRND) Program. As part of the program, Afraxis will partner with the NIH to pursue the ongoing development of the company's disease-modifying treatments for Fragile X syndrome. Fragile X syndrome is a rare genetic disorder that is the most common inherited form of mental retardation.

"TRND collaborations help companies focusing on rare and neglected diseases overcome one of the biggest obstacles facing all drug development companies: advancing programs through that 'valley of death' between identification of a promising compound, and clinical stage development when a program becomes more attractive to a big pharma partner," said Jay Lichter, Ph.D., president and CEO of Afraxis. "This is a tremendous opportunity for Afraxis as the NIH is providing access to state-of-the-art laboratory facilities, the expertise of collaborating NIH scientists, and the financial resources to continue our research and development efforts through the initiation of human clinical trials."

Afraxis is developing disease-modifying treatments for Fragile X syndrome and other central nervous system disorders based on a leadership position in the understanding of PAK biology. Fragile X symptoms can range from learning disabilities to more severe cognitive or intellectual disabilities, such as mental retardation. Fragile X is the most common known cause of autism or "autistic-like" behaviors. The disease is caused by a mutation in the FMR gene on t
'/>"/>

SOURCE Afraxis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. AcroMetrix Renews Contract With Group Services for Americas Blood Centers
11. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:7/10/2014)... 10, 2014   LabStyle Innovations Corp . ... announced the appointment of Professor Richard B. ... Board of Directors. Prof. Stone brings ... to LabStyle as an entrepreneur, venture capitalist public, ... governance expert. He currently serves on the board ...
(Date:7/10/2014)... -- Decision Resources Group finds that over half of ... Drug Administration,s (FDA) approval of Vifor Fresenius Medical Care ... by the FDA in November 2013 for the treatment ... dialysis. Other key findings from the report ... : , Bundling: Based ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... Study) Results Demonstrate ... of VH(R) IVUS in Drug Development, SAN DIEGO, ... [ESC Booth # A2-D403], a leading manufacturer of,intravascular ultrasound ... of its VH(R) IVUS (Virtual Histology IVUS) in,GlaxoSmithKline,s IBIS-2 ...
... 1 Calabar AB, a privately,held pharmaceutical company ... EUR 350,000 equity financing from the investment company,Karolinska ... a phase II study with repeated dosing. "We ... the minor glands will lead to improved outcomes ...
Cached Medicine Technology:Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 2Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 3Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 4
(Date:7/10/2014)... 10, 2014 One week ahead of ... Safety announced today it will extend compensation benefits to ... wages for workers displaced as a result of factory ... inspections have resulted in the closure of five factories ... cases, raising immediate safety concerns. In May, the Alliance—in ...
(Date:7/10/2014)... NY (PRWEB) July 10, 2014 CBPartners, ... sciences industry, has launched a new website. The ... well as increased access to the firm’s thought pieces, ... provides an ideal platform to showcase our insights, capabilities, ... issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
(Date:7/10/2014)... A new study from Colorado School of Public ... health remains a major problem in the Navajo Nation ... among Native Americans is abysmal with more than three ... said Terrence Batliner, DDS, MBA, associate director of the ... of Public Health. "The number one problem is access ...
(Date:7/10/2014)... News) -- Most professional football players who have shoulder ... a new study finds. Shoulder instability is a ... return after surgery to fix the problem has been ... included 60 players who had shoulder stabilization surgery. Ninety ... to play, defined as playing in at least one ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:CBPartners Announces New Website 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Shoulder Surgery Gets NFL Players Back in the Game 2
... Lee, M.D., breast cancer researcher and assistant member ... grant from General Electric,s $100 million healthymagination Challenge ... genetic makeup to determine if they are predisposed ... GE,s healthymagination grant awarding initiative focuses on "finding ...
... Five Indiana University School of Medicine geriatricians are ... nationwide who will share in $2.5 million in career ... IU School of Medicine was one of the top-funded ... Medicine are: , Tochukwu Iloabuchi, M.D., advanced geriatrics ...
... H. Julia Hannay, the John and Rebecca Moores Professor ... 2012 Ester Farfel Award, a symbol of overall career ... faculty member. The annual award carries a cash prize ... honor recognizing the many roles that we may have ...
... Electrocardiograph (EKG) screening of young athletes can help identify those ... study. Researchers screened nearly more than 1,300 young athletes ... history, family history, a physical exam or prior EKG. Six ... cause sudden cardiac death. The study looked at how ...
... public health threats, early diagnosis of infectious diseases is ... globe where conventional medical tools like microscopes and cytometers ... to make disease screening quicker and simpler. ... or fluid samples are placed. Specific changes in the ...
... of small molecules that kill cancer cells caused by ... both cell and mouse models, demonstrate that the small ... proteins, thus killing the infected tumor cells. The ... issue of the journal Chemistry & Biology . ...
Cached Medicine News:Health News:Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks 2Health News:Awards to 5 IU School of Medicine physicians address critical need for geriatricians 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 3Health News:Heart Test Spots Sudden Death Risk in Young Athletes 2Health News:UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity 2Health News:UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity 3Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: